Literature DB >> 2233244

Molecular pathology of type 1 diabetes.

I L Campbell1, L C Harrison.   

Abstract

Evidence from epidemiological and histopathologic studies in humans with autoimmune type 1 (insulin-dependent) diabetes suggests that beta-cell destruction within the islets of Langerhans progresses through a number of stages. In this review we draw on recent experimental evidence in an attempt to define the molecular pathology of these stages. Stage 1 is postulated to be initiated by modification of the beta cell by virus, chemical or other factors, leading to the production of interferon-alpha, hyperexpression of major histocompatibility complex (MHC) class I molecules and induction of MHC class II molecules. Experiments in transgenic mice suggest that overexpression of MHC molecules is in itself detrimental to beta-cell function. Shedding of antigen(s) from dying beta cells in combination with hyperexpression of MHC molecules may be a powerful immunogenic stimulus. Stage 2 commences with infiltration of the islets by immuno-inflammatory cells (termed insulitis). It is proposed that production of cytokines from the infiltrating cells induces "phenotypic switching" in beta cells, with further upregulation of MHC molecules and the induction of intracellular adhesion molecule-1 expression and interleukin-6 production. Together, these properties are seen as a prerequisite for the presentation of autoantigen by beta cells to adherent T lymphocytes and autoimmune activation. The final stage encompasses autoimmune-mediated destruction of the beta cells by the targeted delivery of cytotoxic cytokines and other mediators.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233244

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  14 in total

1.  Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes.

Authors:  M G von Herrath; S Efrat; M B Oldstone; M S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Interleukin-1-beta, tumor necrosis factor-alpha, insulin secretion and oral glucose tolerance in non-diabetic siblings of children with IDDM.

Authors:  A el-Nawawy; T Soliman; O el-Azzouni; A A Abbassy; M N Massoud; S Marzouk; F Ibrahim; L Helal
Journal:  Indian J Pediatr       Date:  1998 May-Jun       Impact factor: 1.967

3.  Permanent neonatal diabetes mellitus: clinical presentation and epidemiology in Oman.

Authors:  B Bappal; P Raghupathy; V de Silva; S M Khusaiby
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-05       Impact factor: 5.747

Review 4.  The immunologic insult in type 1 diabetes.

Authors:  M C Honeyman; L C Harrison
Journal:  Springer Semin Immunopathol       Date:  1993

5.  Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice.

Authors:  I L Campbell; M V Hobbs; J Dockter; M B Oldstone; J Allison
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

6.  Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata.

Authors:  G M Galbraith; J P Pandey
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

7.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 8.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

9.  Nonimmune thyroid destruction results from transgenic overexpression of an allogeneic major histocompatibility complex class I protein.

Authors:  A G Frauman; P Chu; L C Harrison
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

10.  Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM.

Authors:  A Cox; A M Gonzalez; A G Wilson; R M Wilson; J D Ward; C M Artlett; K Welsh; G W Duff
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.